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health-care context was developed, based on the use of
epidemiological and clinical data obtained from literature
and local data on health-care resource utilisation and
health-care unit costs. Only direct medical costs were
analysed. The perspective of the health-care payers (sick
funds and patients) and a time horizon of six months
were taken. The target population was RA patients aged
55, with an average risk of 9-12 points using Fries calcu-
lator. Effectiveness was expressed in terms of the number
of patients free of symptomatic ulcer. On this basis, saved
lives and life years gained were calculated. The cost-effec-
tiveness threshold, calculated on the basis of one-year
haemodialysis treatment cost of 60000 PLN (1 USD  4
PLN), was determined to assess whether celecoxib ther-
apy should be adopted.
RESULTS: The cost-effectiveness analysis showed that
celecoxib treatment of RA patients gives additional life
years for extra costs. The cost per symptomatic ulcer or
death averted for celecoxib, compared with diclofenac,
were 20431 to 20676 and 600887 to 608887 PLN re-
spectively. In the study population, 1 LYG costs 32300
PLN and is below the suggested threshold. One-way sen-
sitivity analysis showed that results are sensitive to
changes in price of celecoxib and the probability of
NSAID-induced GI events. The threshold analysis sug-
gests that celecoxib would be the dominant therapy if its
cost or daily dose were to decrease by 60%.
CONCLUSION: The treatment with celecoxib vs. diclo-
fenac 75 SR in RA may be cost-effective in Poland. Cost/
LYG was below the suggested cost-effectiveness thresh-
old, if avoidance of 1 death generates more than 10 LY.
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OBJECTIVES: To analyze direct medical costs for man-
agement of nonsteroidal anti-inflammatory drug (NSAID)
induced gastrointestinal adverse events, with or without
gastroprotective agents, in patients with osteoarthritis or
rheumatoid arthritis from the perspective of a public
health organization in Hong Kong.
METHODS: A decision-tree was used to analyze, over
six months, the resource utilization associated with five
treatment alternatives: a cyclooxygenase-2 (COX-2) in-
hibitor (celecoxib); NSAID only; NSAID plus H2-recep-
tor antagonist (H2RA); NSAID plus misoprostol, and
NSAID plus proton-pump inhibitor (PPI). Each alterna-
tive could lead to five possible outcomes: no gastrointes-
tinal (GI) toxicity; GI discomforts; symptomatic ulcer;
anaemia with occult bleeding, and serious GI complica-
tions. The probabilities of GI adverse events were taken
from the literature. Resource utilization for all outcomes,
except for anaemia with occult bleeding, was retrieved
from the database of a major public hospital in Hong
Kong. The resource utilization for anaemia with occult
bleeding was gathered by expert interview. A one-way
sensitivity analysis was performed to assess the relative
impact of patients’ underlying GI risk score, based on the
modified version of the Fries risk calculator, on the ex-
pected value of each alternative.
RESULTS: The costs associated with the alternatives, per
base case analysis, were as follows: NSAID plus H2RA
HK$966 (1USD7.8HKD); celecoxib HK$1189; NSAID
alone HK$1293; NSAID plus misoprostol HK$1523,
and, NSAID plus PPI HK$2327. One-way sensitivity
analysis showed that the cost of NSAID plus H2RA was
the lowest in patients with a GI risk score below 15-16,
and the cost of celecoxib therapy was the lowest when
the GI risk score was greater than or equal to 15-16.
CONCLUSION: Based on the decision-tree analysis of
the data obtained, NSAID plus H2RA is the least costly
regimen in patients with low GI risk score and celecoxib
is the least costly alternative in patients with intermediate
to high GI risk score in Hong Kong.
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OBJECTIVE: To ascertain the efficiency of Celecoxib
versus non-steroidal anti-inflammatory drugs (NSAID) in
treating osteoarthritis.
METHODS: The study was performed using a decision
analytic model that represents the daily medical practice
in our country by running two hypothetical cohorts of
10,000 patients either with Celecoxib or any NSAID.
The simple decision tree of the model has two different
branches: a) Celecoxib, and b) NSAID, divided into
NSAID  gastroprotective agents and NSAID alone.
Each branch may follow different clinical evolutions: no
adverse reactions; appearance of gastro-intestinal (G-I)
discomfort; symptomatic ulcers, and severe G-I complica-
tions followed by death. The probabilities for the devel-
opment of these adverse events have been obtained from
medical literature, national statistics (life expectancy) and
a local expert panel. The effectiveness unit chosen was
life-years gained after the use of both options. Only direct
costs were included (medications, additional examina-
tions and analytical tests, days of hospitalization, treat-
ment of ulcers and G-I complications). The time horizon
was six months and the perspective selected was the
Spanish National Health Service (NHS).
RESULTS: The total cost of the cohort treated with Cele-
coxib was 570,456,110 pesetas (US $2,955,731) while
in the cohort treated with NSAIDs this amounted to
340,328,814 pesetas (US $1,763,361). In the Celecoxib
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group, there were nine lives saved compared with the
NSAID group with 18 life-years gained for each death
avoided. The total cost/life saved with Celecoxib was
25,458,588 pesetas (US $131,909) with a cost/life-year
gained of 1,414,366 pesetas (US $7,328) when compared
with the use of NSAIDs.
CONCLUSIONS: The use of Celecoxib instead of
NSAIDs to treat osteoarthritis will produce a lower inci-
dence of severe G-I complications, thus avoiding deaths.
The cost per life-year gained when using Celecoxib is a
reasonable amount, easily covered by the Spanish NHS.
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OBJECTIVES: To perform an economic evaluation on
the short-term costs of managing edema and hyperten-
sion in COX-2-inhibitor-treated patients with osteoar-
thritis (OA) and hypertension (HTN).
METHODS: Two randomized clinical trials (RCT) in
OA/HTN patients showed a significantly higher inci-
dence of systolic blood pressure (SBP) destabilization
(8.7% to 15.6%; RR  0.61, p  .001), edema (4.8% to
8.5%, RR  0.67, p  0.04), and both SBP/edema (0.6%
to 2.2%; RR  0.28, p  0.003) for rofecoxib 25 mg/day
(n  942) compared to celecoxib 200 mg/day (n  960).
The RCT results were projected onto a typical US man-
aged-care organization (MCO) population using: (1) the
age distribution from a large MCO; (2) age- and gender-
specific prevalence of OA and HTN from US government
data; (3) age-specific incidence of cardiorenal events from
pooled RCT data, and (4) prevalence of COX-2 inhibitor
use in a large insurer. We determined resource utilization
and treatment patterns from the published literature and
an expert physician panel. Costs were obtained from
standardized databases and published literature.
RESULTS: For a population of 1,000,000 MCO mem-
bers, 8% of members (n  79,903) are projected to have
OA and HTN, while 2.2% of members (n  21,594) have
OA /HTN and use a COX-2 inhibitor. From the analysis,
the number of additional events predicted to occur with
rofecoxib (relative to celecoxib) are: SBP destabilization
(n  1144); edema-alone (n  453); edema and SBP de-
stabilization (n  345). The total cost savings of treat-
ment with celecoxib would be $474,007. Translated into
other parameters, the cost savings from the celecoxib us-
age would be $1.83 in per patient per month costs, and
$0.24 in the daily cost of COX-2 inhibitor use for an av-
erage patient.
CONCLUSION: The short-term management of SBP de-
stabilization and edema adds to the cost of rofecoxib treat-
ment, relative to celecoxib. Clinicians and payers should
not ignore the clinical effects and economic impact of ar-
thritis medications on blood pressure and edema.
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RA is a chronic disease that affects 0.5 to 1% of the pop-
ulation. The economic impact of RA on individuals and
society is enormous and the costs of RA rise steeply with
disease severity. A therapy that reduces disease progres-
sion could be expected to lead to reductions in resource
use as well as maintaining quality of life.
OBJECTIVE: To estimate the costs and consequences of
adding infliximab to the care of patients with severe rheuma-
toid arthritis (RA) already being treated with methotrexate.
METHODS: Estimates of the impact of infliximab on dis-
ease progression were obtained from the ATTRACT trial
in which 428 RA patients were randomly assigned to
methotrexate or methotrexate plus infliximab. Since pa-
tients in the ATTRACT trial were followed for only 54
weeks, we developed a Markov model in order to estimate
the long-term consequences of RA. The model was based
on a cohort (ARAMIS) involving 4258 consecutively en-
rolled RA patients followed in nine centres in USA and
Canada. Markov health states were based on the Health
Assessment Questionnaire and on drug treatment. For the
first year, costs were calculated using the resource utiliza-
tion by UK patients in the ATTRACT trial and applying
UK unit costs. Long-term costs were obtained from the
Norfolk Arthritis Register (NOAR) cohort. Utilities were
based on visual analogue scale assessments in ATTRACT
(first year) and ARAMIS (long-term).
RESULTS: In the base-case analysis, the incremental cost
per QALY of infliximab was £33,618. Assuming radio-
graphic stabilization of joint disease for patients treated
with infliximab after the first year of treatment (as sug-
gested in the long-term data from the ATTRACT trial)
the cost-effectiveness ratio falls to £5111 per QALY. Sen-
sitivity analyses were performed to allow for uncertainty
in some of the estimates.
CONCLUSION: Infliximab is likely to be a cost-effective
treatment for patients suffering from severe RA.
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